ABCC7 p.Cys225Arg
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 16442101
[PubMed]
Frelet A et al: "Insight in eukaryotic ABC transporter function by mutation analysis."
No.
Sentence
Comment
371
The C225R mutant exhibits cAMP-dependent chloride fluxes while the protein is poorly expressed but fully glycosylated.
X
ABCC7 p.Cys225Arg 16442101:371:4
status: NEW
PMID: 10898518
[PubMed]
Kunzelmann K et al: "Control of epithelial Na+ conductance by the cystic fibrosis transmembrane conductance regulator."
No.
Sentence
Comment
190
Analysis of C225R-CFTR and R1066C-CFTR.
X
ABCC7 p.Cys225Arg 10898518:190:12
status: NEW
PMID: 19236881
[PubMed]
Enquist K et al: "Membrane-integration characteristics of two ABC transporters, CFTR and P-glycoprotein."
No.
Sentence
Comment
113
For CFTR, we chose mutations located in TM1CFTR (F87L, G91R), TM3CFTR (P205S, L206W), TM4CFTR (C225R), TM5CFTR (DF311, G314E), TM6CFTR (R334L/W, I336K/R/D, I340N/S, L346P, R347L/H), TM8CFTR (S909I, S912L), TM9CFTR (I1005R, A1006E), TM10CFTR (Y1032N), and TM12CFTR (M1137R, ΔM1140, M1140K), or close to the TM region of TM1CFTR (R74W, L102R/P), TMF2CFTR (R117P/L, L137P), and TM11CFTR (M1101K/R).
X
ABCC7 p.Cys225Arg 19236881:113:95
status: NEW115 As seen in Supplementary Data Table S2, only a few of the tested mutations in the 19 residue long CFTR TM segments alter the insertion efficiency significantly: TM4CFTR (C225R) (decrease from 88% to 34%), TM6CFTR (I336K/R/D) (decrease from 55% to 34%, 36% and 35%, respectively), TM6CFTR (I340N/S) (decrease from 55% to 32% and 35%, respectively), TM6CFTR (L346P) (decrease from 55% to 14%,), and TM12CFTR (ΔM1140) (decrease from 34% to 7%).
X
ABCC7 p.Cys225Arg 19236881:115:170
status: NEW109 For CFTR, we chose mutations located in TM1CFTR (F87L, G91R), TM3CFTR (P205S, L206W), TM4CFTR (C225R), TM5CFTR (DF311, G314E), TM6CFTR (R334L/W, I336K/R/D, I340N/S, L346P, R347L/H), TM8CFTR (S909I, S912L), TM9CFTR (I1005R, A1006E), TM10CFTR (Y1032N), and TM12CFTR (M1137R, ƊM1140, M1140K), or close to the TM region of TM1CFTR (R74W, L102R/P), TMF2CFTR (R117P/L, L137P), and TM11CFTR (M1101K/R).
X
ABCC7 p.Cys225Arg 19236881:109:95
status: NEW111 As seen in Supplementary Data Table S2, only a few of the tested mutations in the 19 residue long CFTR TM segments alter the insertion efficiency significantly: TM4CFTR (C225R) (decrease from 88% to 34%), TM6CFTR (I336K/R/D) (decrease from 55% to 34%, 36% and 35%, respectively), TM6CFTR (I340N/S) (decrease from 55% to 32% and 35%, respectively), TM6CFTR (L346P) (decrease from 55% to 14%,), and TM12CFTR (ƊM1140) (decrease from 34% to 7%).
X
ABCC7 p.Cys225Arg 19236881:111:170
status: NEW
PMID: 10923036
[PubMed]
Claustres M et al: "Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France."
No.
Sentence
Comment
109
h M1K, K14X, W19X, 211delG, G27E, R31C, 237insA, 241delAT, Q39X, 244delTA, 296+2T>C, 297-3C>T, W57X+F87L, 306delTAGA, P67L, A72D, 347delC, R75Q, 359insT, 394delT, 405+4A>G, Q98R, 457TAT>G, R117H+5T, R117H+I1027T, R117L, R117P, H139R, A141D, M152V, N186K, D192N, D192del, E193X, 711+1G>A, 711+3A>G, 712-1G>T, L206F, W216X, C225R, Q237E, G241R, 852del22, 876-14del12, 905delG, 993del5, E292K, Y304X, F311del, 1161delC, R347L, R352Q, W361R, 1215delG, S364P, S434X, D443Y, S466X, C491R, T501A, I506T, F508C, I507del+F508C, F508del+L467F, 1774delCT, R553G, 1802delC, 1806delA, A559E, Y563N, 1833delT, Y569C, Y569H, Y569X, G576X, G576A, T582I, 1898+3A>G+186-13C>G, 1918delGC, R600G, L610S, G628R, 2043delG, 2118del4, E664X, 2174insA, Q689X, K698R, K716X, L732X, 2347delG, 2372del8, R764X, 2423delG, S776X, 2634insT, 2640delT, C866Y, 2752-1G>T, W882X, Y913C, V920M, 2896insAG, H939D, H939R, D979V, D985H, D993Y, 3120G>A, I1005R, 3195del6, 3293delA, 3320ins5, W1063X, A1067T, 3359delCT, T1086I, W1089X, Y1092X+S1235R, W1098X, E1104X, R1128X, 3532AC>GTA, 3548TCAT>G, M1140del, 3600G>A, R1162L, 3667ins4, 3732delA+K1200E, S1206X, 3791delC, S1235R+5T, Q1238R, Q1238X, 3849+4A>G, T1246I, 3869insG, S1255P, R1283K, F1286S, 4005+1G>T, 4006-8T>A, 4015delA, N1303H, N1303I, 4172delGC, 4218insT, 4326delTC, Q1382X, 4375-1C>T, 4382delA, D1445N, CF40kbdel4-10, Cfdel17b.
X
ABCC7 p.Cys225Arg 10923036:109:322
status: NEW
PMID: 9374552
[PubMed]
Fanen P et al: "Cystic fibrosis phenotype associated with pancreatic insufficiency does not always reflect the cAMP-dependent chloride conductive pathway defect. Analysis of C225R-CFTR and R1066C-CFTR."
No.
Sentence
Comment
2
C225R and R1066C are both associated with pancreatic insufficiency, but the former mutation is associated with mild and unusual lung disease, whereas the latter is associated with severe lung disease.
X
ABCC7 p.Cys225Arg 9374552:2:0
status: NEW4 Immunoprecipitation and functional studies showed that cells transfected with C225R-CFTR exhibit cAMP-dependent chloride fluxes; C225R-CFTR protein is poorly expressed but fully glycosylated and can be compared with R117H-CFTR.
X
ABCC7 p.Cys225Arg 9374552:4:78
status: NEWX
ABCC7 p.Cys225Arg 9374552:4:129
status: NEW13 The first lies within the fourth putative membrane-spanning domain and the second within the fourth intracellular loop of the CFTR protein, replacing a cysteine by an arginine at position 225 and an arginine by a cysteine at position 1066, respectively (6).
X
ABCC7 p.Cys225Arg 9374552:13:152
status: NEW15 Immunoprecipitation and functional analysis using a halide- sensitive indicator showed that cells transfected with C225R-CFTR exhibit cAMP-dependent chloride fluxes; C225R-CFTR protein is poorly expressed but fully glycosylated.
X
ABCC7 p.Cys225Arg 9374552:15:115
status: NEWX
ABCC7 p.Cys225Arg 9374552:15:166
status: NEW23 Three mutants, C225R, R1066C, and R117H, were constructed.
X
ABCC7 p.Cys225Arg 9374552:23:15
status: NEW57 RESULTS Three mutated CFTR proteins (C225R-, R1066C-, and R117H-CFTR) and wild-type CFTR were transiently expressed in HeLa cells and analyzed at the mRNA, protein, and functional levels.
X
ABCC7 p.Cys225Arg 9374552:57:37
status: NEW63 A, Northern blot analysis; B, immunoprecipitation assay using mAb 24-1 (Genzyme) of mock-transfected HeLa cells expressing wild-type and mutant CFTRs without (left panel) and with (right panel) sodium butyrate treatment at the same exposure time; C, immunoprecipitation assay of R1066C- and ⌬F508-transfected cells grown at 26 or 37 °C. TABLE I Summary of the MEQ assay results Cell type Wild-type R117H C225R R1066C C225R ϩ NaBd R1066C ϩ NaBd pECE All responding 60 (30)a 9 (16)a 8 (8)a 0 11 (22)a 0 0 Fast 30 (50)b 3 (33)b 0 0 3 (27)b 0 0 ⌬Fstim/⌬Fbasal 13.5 Ϯ 6.8c 8 Ϯ 1.7c 22.3 Ϯ 7.1c Range 6-27 6-9 16-30 Slow 30 (50)b 6 (66)b 8 (100)b 0 8 (73)b 0 0 ⌬Fstim/⌬Fbasal 3.4 Ϯ 1.0c 2.4 Ϯ 0.5c 2.9 Ϯ 1.4c 3.4 Ϯ 1.0c Range 2-5 2-3 1.5-5 1.5-5 Total 200 56 100 100 50 50 60 a Percentage of all cells.
X
ABCC7 p.Cys225Arg 9374552:63:416
status: NEWX
ABCC7 p.Cys225Arg 9374552:63:429
status: NEW67 C225R-CFTR expression showed a faint band C or B, indicating that some mutant protein matured and reached the cell surface.
X
ABCC7 p.Cys225Arg 9374552:67:0
status: NEW70 The intensity of bands C and B of wild-type, R117H- and C225R-CFTR increased markedly, and the ratio of bands C/B was similar in treated wild-type, R117H-, and C225R-CFTR cells.
X
ABCC7 p.Cys225Arg 9374552:70:56
status: NEWX
ABCC7 p.Cys225Arg 9374552:70:160
status: NEW81 When exposed to the stimulatory mixture, 8% of C225R-CFTR cells showed an increased rate of change in MEQ fluorescence, indicating the activation of a cAMP-dependent anion pathway.
X
ABCC7 p.Cys225Arg 9374552:81:47
status: NEW84 To determine if increased protein synthesis influenced the function of the C225R and R1066C mutants, we pretreated cells with 5 mM sodium butyrate for 18-20 h. R117H- and wild-type-CFTR were not tested since they were fully responsive in untreated conditions.
X
ABCC7 p.Cys225Arg 9374552:84:75
status: NEW85 After treatment with butyrate, 22% of C225R-CFTR cells were responsive; of these, 27 and 73% were fast and slow responsive, respectively (Table I).
X
ABCC7 p.Cys225Arg 9374552:85:38
status: NEW87 These results strengthen the conclusion that C225R-CFTR protein is correctly processed to the plasma membrane.
X
ABCC7 p.Cys225Arg 9374552:87:45
status: NEW94 B, HeLa cells transfected with C225R-CFTR with and without sodium butyrate (NaB) treatment (⌬Fstim/⌬Fbasal ϭ 22 and 1.5 for C225R with and without sodium butyrate, respectively).
X
ABCC7 p.Cys225Arg 9374552:94:31
status: NEWX
ABCC7 p.Cys225Arg 9374552:94:144
status: NEW96 CFTR Mutations Associated with Pancreatic Insufficiency atUniversityofNorthCarolinaatChapelHill,onOctober25,2012www.jbc.orgDownloadedfrom DISCUSSION We analyzed the structure-function relationships of two mutations, C225R and R1066C, that we had identified in CF patients with pancreatic insufficiency (6) and compared the properties of those mutations with those of wild-type-CFTR and R117H-CFTR.
X
ABCC7 p.Cys225Arg 9374552:96:218
status: NEW97 C225R was found in a compound heterozygote for the ⌬F508 mutation and was associated with pancreatic insufficiency, normal lung function, and asthma.
X
ABCC7 p.Cys225Arg 9374552:97:0
status: NEW102 To our knowledge, this is the first reported expression of the C225R-CFTR mutant and the first description of a transmembrane mutant associated with a severe phenotype (PI).
X
ABCC7 p.Cys225Arg 9374552:102:63
status: NEW103 Heterologous expression of this mutant in HeLa cells showed that C225R-CFTR protein elicited cAMP-dependent chloride fluxes.
X
ABCC7 p.Cys225Arg 9374552:103:65
status: NEW104 It thus seems that the pancreatic insufficiency associated with the C225R mutation cannot be fully explained by defective chloride conduction through the mutant CFTR protein.
X
ABCC7 p.Cys225Arg 9374552:104:68
status: NEW105 The processing of C225R-CFTR resembles that of R117H-CFTR.
X
ABCC7 p.Cys225Arg 9374552:105:18
status: NEW107 Both mutants are associated with mild lung disease, but R117H is associated with PS whereas C225R is associated with PI.
X
ABCC7 p.Cys225Arg 9374552:107:92
status: NEW117 At the molecular level, cysteine replacement, as in C225R and R1066C, may lead to the disruption or creation of disulfide bonds between cysteines and thereby change the channel properties.
X
ABCC7 p.Cys225Arg 9374552:117:52
status: NEW
PMID: 8844213
[PubMed]
Morral N et al: "Haplotype analysis of 94 cystic fibrosis mutations with seven polymorphic CFTR DNA markers."
No.
Sentence
Comment
106
(1992) Dork et al. (1994a) Malone et al. (personal communication) Claustreset al. (1992) Ferec et al. (1992) Fanen et al. (1992) lvaschenko et al. (1991) T. Dork (personal communication) Dean et al. (1990) Dork et al. (1994a) Ferec et al. (1992) Bozon et al. (1994) Costes et al. (personal communication) Fanen et al. (1992) Audrezet et al. (personal communication) Zielenski et al. (1991a) Zielenski et al. (1991a) Granell et al. (1992) Highsmith et al. (1990) Mercier et al. (1993b) Vidaud et al. (1990) Fanen et al. (1992) Fanen et al. (1992) Dork et al. (1994b) (continued) HAPLOTYPESFOR 94 CF MUTATIONS TABLE2. CFTR HaplotvpesforDiallelic and Multiallelic DNA Markers for 94 CF Mutations"(Continued) ~~ ~ J44-GAIT- 8CA-17BTA- No. of TSU-TUB20 17BCA Mutation chromosomes % Normal Laboratory Reference 1-6-1-2 (9.1%) 1-6-2-2 (8.9%) 1-7-1-2 (3.4%) 1-7-2-2 (2.6%) 2-7-1-1 (1.2%) 2-7-2-2 (0.7%) 17-7-16 16-7-18 16-7-17 15-7-17 24-31-13 23-52-13 23-34-13 23-33-14 23-33-13 23-32-13 23-31-13 23-30-13 23-21-19 23-18-13 22-35-13 22-31-13 22-30-13 21-31-13 19-33-13 18-45-13 18-37-13 18-35-13 17-57-11 17-55-13 17-55-11 17-54-11 17-53-11 17-52-11 17-51-11 17-33-13 16-46-13 16-45-13 16-44-13 16-42-13 16-35-13 16-30-13 16-30-13 16-7-17 16-21-19 L107% L1077P 24ldelAT L719X A1507 3849+10kbC-T 2184insA 2991de132 G551D 1154insTC V520F R560T 4114ATA+lT 3667de14 435insA Q414X C225R Q39X N1303K R1162X H199Y G542X G542X w1204x R347H G542X AF50gb N1303K 2143delT 3849f 10kbC-T N1303K 681delC R347H A455E N1303K A120T 621+1 h T 574delA 1221delCT F311L R560K R553X R533X R553X Q552X R553X Q552X R116W R553X 1898+5 h T 3272-26A-G 1717-1hA 1342-2A-C A1507 2869insG 2869insG E92X 4374+1 h T 2183AA-G R117H 1609delCA I336K W1063X 1 1 1 1 6 1 3 1 1 22 17 1 1 1 1 1 1 1 1 1 1 1 1 1 17 1 1 4 157 7 1 2 2 1 1 2 2 1 9 1 1 1 1 1 1 6 1 1 1 2 1 3 2 1 3 1 1 1 4 2 4 1 1 - - 10.33 1.45 - - 0.48 1.45 - 0.24 1.45 0.24 - - - - 0.24 0.48 - - - - - - 0.49 0.48 - 0.24 0.24 0.24 - - - - - 0.72 0.24 0.72 - t h fP h b.fb,fP h b,fp.t t h b.fb.fp,h,t b.fb.fp,h,t t t t h b h h fP h fP fb b fP b.fb,fP,h.t fP fb b,fP,t b.fb,fp,h,t b.fb,h h h h,t t fb t b b b.fb.t fP fb fb tb h fP h h t t b h t h b b h h b,fb,h fP.h b h fP fP Bozon et al. (1994) Fanen et al. (1992) Dork et al. (1994a) Kerem et al. (1990) Dork et al. (1994~) Cutting et al. (1990) Kerem et al. (1990) lannuui et d.
X
ABCC7 p.Cys225Arg 8844213:106:1371
status: NEW
PMID: 1379210
[PubMed]
Fanen P et al: "Molecular characterization of cystic fibrosis: 16 novel mutations identified by analysis of the whole cystic fibrosis conductance transmembrane regulator (CFTR) coding regions and splice site junctions."
No.
Sentence
Comment
67
T C225R R334W G542X G551D 1717-l G -+ A K710X Lys -b Stop at 710 A-+Tat2260 G628R Gly + Arg at 628 G+Aat2014 2043 delG Frameshift 1 -bp deletion W846X Trp --, Stop at 846 G-+Aat2670 2789 + 5 G - A Splice mutation G + A at 2789 + 5 Y913C Tyr --) Cys at 913 A-,Gat2870 3272-26 A -+ G Splice mutation A + G at 3272-26 W1063X Trp -+ Stop at 1063 G+Aat3321 R1066C Arg + Cys at 1066 C+Tat3328 Y1092X Tyr + Stop at 1092 C + A at 3408 3659delC Frameshift l-bp deletion 19 3732deIA Frameshift 1-bp deletion 19 K1200E Lys --, Glu at 1200 A+Gat3730 19 R1162X Arg - Stop at 1162 C + T at 3616 19 W1282X Trp + Stop at 1282 G+Aat3978 20 N1303K Asn -+ Lys at 1303 C -+ G at 4041 21 4374 + 1 G + A Splice mutation G+Aat4374+ 1 Intron 23 Asp + Gly at 44 Frameshift Frameshift Gly + Arg at 178 Splice mutation Cys + Arg at 225 Arg + Trp at 334 Gly + Stop at 542 Gly + Asp at 551 Splice mutation A+Gat263 2 2bp deletion 2 1-bp deletion 4 G --, A at 664 5 G + Tat 711 + 1 Intron 5 T+Cat805 6a C + Tat 1132 7 G + T at 1756 11 G+Aat1784 11 G + A at 1717-l Intron 10 Haplotype Restriction (XV-2c, KM-19) site change Reference A B A A or C A D A B, D B B Hinfl(-) - - - - SecI (+) MspI (6) - Mb01 (+) - 13 13 13 14a Intron 14 b 15 Intron 17a 17b 17b 17b C A B A D A A C B C XmnI (-) - - - MnlI (-) - - This study This study This study Zielenski et al. (1991) Zielenski et al. (1991) This study Gasparini et al. (1991b) Kerem et al. (1990) Cutting et al. (1990) Kerem et al. (1990); Guillermit et al. (1990) This study This study This study Vidaud et al. (1990a) Highsmith et al. (1990) Vidaud et al. (1990a) This study This study This study Bozon (personal communication) Kerem et al. (1990) This study Together with 3732delA Gasparini et al. (1991b) Vidaud et al. (1990a) Osborne et al. (1991) This study Note. Previously undescribed mutations are shown in bold type.
X
ABCC7 p.Cys225Arg 1379210:67:2
status: NEW74 The C225R mutation was detected in exon 6a in a CF patient with pancreatic disease requiring pancreatic enzyme supplementation and who also bore the AF508 deletion.
X
ABCC7 p.Cys225Arg 1379210:74:4
status: NEW